Icahn Speculation Around Valeant (VRX) Grows Following Interview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Valeant Pharma (VRX) At Lows Into the Close
November 4, 2015 3:43 PM ESTValeant Pharma (NYSE: VRX) is trading near the lows into the close. Shares are down 6% to $92. Today's senate hearing on drug pricing, the 'missing piece' hit piece and reports from Reuters that OptumRx caught on to odd billing at Valeant-linked pharmacy more than a year ago, are all weighting.
... More